JP3147916B2
(ja)
*
|
1991-03-08 |
2001-03-19 |
森永製菓株式会社 |
体外免疫方法
|
EP0749488A1
(de)
*
|
1994-03-03 |
1996-12-27 |
Genentech, Inc. |
Anti il - 8 monoklonale antikörper für die behandlung von entzündlichen erkrankungen
|
US5874080A
(en)
*
|
1994-03-03 |
1999-02-23 |
Genentech, Inc. |
Anti-IL-8 monoclonal antibodies for treatment of asthma
|
AU743758B2
(en)
|
1997-04-07 |
2002-02-07 |
Genentech Inc. |
Anti-VEGF antibodies
|
EP0971959B1
(de)
|
1997-04-07 |
2005-12-28 |
Genentech, Inc. |
Humanisierte antikörper und verfahren zu ihrer herstellung
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
PT1181319E
(pt)
|
1999-05-28 |
2009-07-14 |
Genentech Inc |
Anticorpos quiméricos contra dr4 e suas utilizações
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
DK2803367T3
(en)
|
1999-06-25 |
2018-04-16 |
Immunogen Inc |
Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
|
ES2329437T3
(es)
|
1999-06-25 |
2009-11-26 |
Genentech, Inc. |
Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
|
CN101289511A
(zh)
|
2000-04-11 |
2008-10-22 |
杰南技术公司 |
多价抗体及其应用
|
JP2004512262A
(ja)
|
2000-06-20 |
2004-04-22 |
アイデック ファーマスーティカルズ コーポレイション |
非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ
|
ATE415978T1
(de)
|
2000-07-27 |
2008-12-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
DK2000545T3
(da)
|
2001-06-20 |
2011-11-28 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
|
US20030013081A1
(en)
|
2001-06-26 |
2003-01-16 |
Olson William C. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
NZ573740A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184
|
KR20050036875A
(ko)
*
|
2001-10-15 |
2005-04-20 |
이뮤노메딕스, 인코오포레이티드 |
직접 표적형의 결합 단백질
|
AU2002367318B2
(en)
|
2002-01-02 |
2007-07-12 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2476166C
(en)
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
CN1649902B
(zh)
|
2002-03-01 |
2011-04-13 |
免疫医疗公司 |
内在化抗-cd74抗体和使用方法
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
ES2429112T3
(es)
|
2002-04-10 |
2013-11-13 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
BR0311799A
(pt)
|
2002-06-14 |
2005-05-10 |
Immunomedics Inc |
Anticorpo monoclonal hpam4
|
JP2006515154A
(ja)
*
|
2002-06-21 |
2006-05-25 |
セントカー・インコーポレーテツド |
モノクローナル抗体の作成方法
|
PL214010B1
(pl)
|
2002-07-15 |
2013-06-28 |
Genentech Inc |
Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
|
AU2003248982B2
(en)
*
|
2002-08-01 |
2009-12-10 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
US20080260744A1
(en)
*
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
JP2006513702A
(ja)
*
|
2002-09-09 |
2006-04-27 |
ヌラ インコーポレーティッド |
Gタンパク質共役受容体およびその使用
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
EP2246363A1
(de)
|
2002-11-15 |
2010-11-03 |
Novartis Vaccines and Diagnostics, Inc. |
Verfahren zur Prävention und Behandlung von Krebsmetastasen und Knochenschwund, der mit Krebsmetastasen assoziiert ist
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
SI1572744T1
(sl)
|
2002-12-16 |
2010-09-30 |
Genentech Inc |
Imunoglobulinske variante in njihove uporabe
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
EP1596806A4
(de)
*
|
2003-01-27 |
2007-08-29 |
Biogen Idec Inc |
Zusammensetzungen und verfahren zur behandlung von krebs mit igsf9 und liv-1
|
EP1597280B2
(de)
|
2003-02-26 |
2016-08-24 |
Institute for Research in Biomedicine |
Monoklonale antikörperproduktion durch ebv transformation von b-zellen
|
GB2398783A
(en)
|
2003-02-26 |
2004-09-01 |
Antonio Lanzavecchia |
A method for producing immortalised human B memory lymphocytes
|
LT2335725T
(lt)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
Didelės koncentracijos antikūno ir baltymo kompozicijos
|
US20040202658A1
(en)
|
2003-04-09 |
2004-10-14 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
|
AU2004251161A1
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
JP2007526220A
(ja)
|
2003-06-05 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
B細胞疾患の併用療法
|
ES2751414T5
(es)
|
2003-07-08 |
2024-04-23 |
Novartis Pharma Ag |
Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
|
EP1648512A4
(de)
|
2003-07-31 |
2009-01-21 |
Immunomedics Inc |
Anti-cd19 antikörper
|
WO2005014618A2
(en)
*
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
DK1725249T3
(en)
|
2003-11-06 |
2014-03-17 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugating to ligands.
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
KR101352853B1
(ko)
|
2004-01-07 |
2014-02-04 |
조마 테크놀로지 리미티드 |
M-csf-특이적 단일클론 항체 및 그것의 사용
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
WO2005113003A2
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
AR049200A1
(es)
|
2004-06-04 |
2006-07-05 |
Genentech Inc |
Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
|
WO2006002532A1
(en)
*
|
2004-07-01 |
2006-01-12 |
Waratah Pharmaceuticals, Inc. |
Methods and compositions using cd3 agonists
|
EP1771474B1
(de)
|
2004-07-20 |
2010-01-27 |
Genentech, Inc. |
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
|
US7732131B2
(en)
|
2004-08-03 |
2010-06-08 |
Innate Pharma S.A. |
Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
ES2557587T3
(es)
|
2004-12-28 |
2016-01-27 |
Innate Pharma |
Anticuerpos monoclonales contra NKG2A
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
PL1846030T3
(pl)
|
2005-01-21 |
2019-05-31 |
Genentech Inc |
Ustalone dawkowanie przeciwciał her
|
WO2006081171A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
PL1853718T3
(pl)
|
2005-02-15 |
2016-01-29 |
Univ Duke |
Przeciwciała anty-CD19 i zastosowania w onkologii
|
UA95902C2
(ru)
|
2005-02-23 |
2011-09-26 |
Дженентек, Инк. |
Способ увеличения времени развития заболевания или выживаемости у раковых пациентов
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
JP5167473B2
(ja)
*
|
2005-03-03 |
2013-03-21 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
抗血管新生化合物
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
US7858843B2
(en)
|
2005-06-06 |
2010-12-28 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
WO2007008848A2
(en)
*
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
US8343928B2
(en)
|
2005-07-07 |
2013-01-01 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
|
AU2006272750B2
(en)
*
|
2005-07-22 |
2011-09-29 |
Cytodyn, Inc. |
Methods for reducing viral load in HIV-1-infected patients
|
US20080233118A1
(en)
*
|
2005-07-28 |
2008-09-25 |
Novartis Ag |
Uses Of Antibody To M-Csf
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
EP1934260B1
(de)
|
2005-10-14 |
2017-05-17 |
Innate Pharma |
Zusammensetzungen und methoden zur behandlung proliferierender krankheiten
|
EP1962584A2
(de)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Neuartige genunterbrechung, dazugehörige zusammensetzungen und verfahren
|
US7625759B2
(en)
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
WO2007111661A2
(en)
|
2006-03-20 |
2007-10-04 |
Xoma Technology Ltd. |
Human antibodies specific for gastrin materials and methods
|
MX2008011905A
(es)
|
2006-03-21 |
2008-09-30 |
Genentech Inc |
Terapia de combinacion.
|
SG170728A1
(en)
|
2006-03-23 |
2011-05-30 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US9044461B2
(en)
|
2006-04-07 |
2015-06-02 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
JP5524610B2
(ja)
*
|
2006-04-07 |
2014-06-18 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク |
トランスコバラミン受容体ポリペプチド、核酸およびその調節因子、ならびに細胞の増殖の調節ならびにガンおよびコバラミン欠損症の処置に使用する関連方法
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
CA2652945C
(en)
|
2006-05-30 |
2015-06-02 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
ES2452067T3
(es)
|
2006-08-04 |
2014-03-31 |
Novartis Ag |
Anticuerpo específico para EPHB3 y usos del mismo
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
EA201201533A1
(ru)
|
2006-08-18 |
2014-11-28 |
Новартис Аг |
Prlr-специфическое антитело и его применения
|
EP2423333A1
(de)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognosemarker und therapeutische Targets für Lungenkrebs
|
WO2011008990A1
(en)
|
2009-07-15 |
2011-01-20 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
CA2667574A1
(en)
|
2006-10-27 |
2008-06-12 |
Roger A. Sabbadini |
Compositions and methods for binding sphingosine-1-phosphate
|
CN101687031B
(zh)
*
|
2006-10-27 |
2014-05-14 |
勒帕斯公司 |
用于治疗眼疾和眼病的组合物及方法
|
AU2007318912B2
(en)
|
2006-11-10 |
2011-03-03 |
Covx Technologies Ireland Limited |
Anti-angiogenic compounds
|
ES2543350T3
(es)
|
2006-11-27 |
2015-08-18 |
Diadexus, Inc. |
Composiciones de anticuerpos de Ovr110 y métodos de uso
|
CA2672120A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonistic antibodies against ephb3
|
US20090186034A1
(en)
*
|
2006-12-19 |
2009-07-23 |
Genetech, Inc. |
Gene expression markers for inflammatory bowel disease
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
JP2010517529A
(ja)
*
|
2007-02-02 |
2010-05-27 |
アムジエン・インコーポレーテツド |
ヘプシジン及びヘプシジン抗体
|
AU2008218199B2
(en)
|
2007-02-22 |
2013-10-31 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
PL2155248T3
(pl)
|
2007-04-12 |
2015-12-31 |
Brigham & Womens Hospital Inc |
Celowanie w ABCB5 w terapii nowotworowej
|
US7959916B2
(en)
|
2007-04-23 |
2011-06-14 |
Fred Hutchinson Cancer Research Center |
Negative immunomodulation of immune responses by ERp5
|
ES2433967T3
(es)
|
2007-05-14 |
2013-12-13 |
The University Of Chicago |
Productos de fusión anticuerpo-LIGHT como productos terapéuticos de cáncer
|
DK2164992T3
(en)
*
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
EP2592156B1
(de)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Genexpressionsmarker für Tumorresistenz gegen Behandlung mit HER2-Inhibitor
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
AU2008284015B2
(en)
|
2007-08-03 |
2014-05-15 |
Musc Foundation For Research Development |
Human monoclonal antibodies and methods for producing the same
|
WO2009028581A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Cancer-related genes, cdca5, epha7, stk31 and wdhd1
|
RU2010111120A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
EP2200631A1
(de)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
MX2010005244A
(es)
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AU2008334095A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
CA2710252C
(en)
|
2007-12-20 |
2017-03-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
AU2009206306B2
(en)
|
2008-01-25 |
2013-06-06 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
PL2247620T3
(pl)
|
2008-01-31 |
2017-08-31 |
Genentech, Inc. |
Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
|
DK3153526T3
(da)
|
2008-01-31 |
2020-12-14 |
Inst Nat Sante Rech Med |
Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
|
CN103399144B
(zh)
|
2008-02-25 |
2015-10-28 |
雀巢产品技术援助有限公司 |
用抗体阵列选择乳腺癌治疗药物
|
AU2009223688B2
(en)
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
WO2009139822A1
(en)
|
2008-05-01 |
2009-11-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
US8293714B2
(en)
|
2008-05-05 |
2012-10-23 |
Covx Technology Ireland, Ltd. |
Anti-angiogenic compounds
|
SI2307051T1
(sl)
|
2008-07-08 |
2015-04-30 |
Oncomed Pharmaceuticals, Inc. |
Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
NZ590330A
(en)
*
|
2008-07-21 |
2012-08-31 |
Immunomedics Inc |
Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
US8273541B2
(en)
|
2008-09-17 |
2012-09-25 |
Innate Pharma |
Compositions and methods for detecting TLR3
|
CA2738176C
(en)
|
2008-09-23 |
2012-01-10 |
Hema-Quebec |
Method for polyclonal immunoglobulin g production by human b cells
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AU2009313902B9
(en)
|
2008-11-13 |
2014-03-27 |
The General Hospital Corporation |
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
|
EP2361085B9
(de)
|
2008-11-22 |
2019-01-02 |
F.Hoffmann-La Roche Ag |
Verwendung des anti-vegf-antikörpers in kombination mit chemotherapie zur behandlung von brustkrebs
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
US20110223169A1
(en)
*
|
2008-11-26 |
2011-09-15 |
Stern Michael E |
Il-17 antibody inhibitor for treating dry eye
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
EP2374001A4
(de)
*
|
2008-12-05 |
2013-03-13 |
Lpath Inc |
Antikörperdesign unter verwendung von anti-lipid-antikörper-kristallstrukturen
|
KR20210060670A
(ko)
|
2008-12-09 |
2021-05-26 |
제넨테크, 인크. |
항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
ES2539045T3
(es)
|
2009-01-19 |
2015-06-25 |
Innate Pharma |
Anticuerpos anti-KIR3D
|
EP3470087A1
(de)
|
2009-02-13 |
2019-04-17 |
Immunomedics, Inc. |
Lyophilisierte zusammensetzungen von immunkonjugaten mit einem intrazellulär spaltbaren linker
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
US20120121591A1
(en)
|
2009-03-20 |
2012-05-17 |
Amgen Inc. |
SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
EP2419446A4
(de)
*
|
2009-04-17 |
2013-01-23 |
Lpath Inc |
Humanisierte antikörperzusammensetzungen und verfahren zur bindung von lysophosphatidsäure
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AU2010270761A1
(en)
|
2009-07-07 |
2012-01-19 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
EP2451844B1
(de)
|
2009-07-10 |
2015-04-22 |
Innate Pharma |
Tlr3-binder
|
US20110033486A1
(en)
|
2009-07-20 |
2011-02-10 |
Abbas Alexander R |
Gene expression markers for crohn's disease
|
US20130017188A1
(en)
|
2009-07-31 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
SG178419A1
(en)
|
2009-08-15 |
2012-04-27 |
Genentech Inc |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
CA2772945A1
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
RU2558797C2
(ru)
|
2009-10-20 |
2015-08-10 |
Нестек С.А. |
Способы выявления онкогенных слитых белков, основанные на анализе близкого взаимного расположения
|
MX2012004617A
(es)
|
2009-10-22 |
2012-05-08 |
Genentech Inc |
Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
|
NZ623607A
(en)
|
2009-10-23 |
2016-07-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
CA2781532A1
(en)
|
2009-11-20 |
2011-05-26 |
Amgen Inc. |
Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
|
MX338694B
(es)
|
2009-11-30 |
2016-04-27 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
EP2523680A4
(de)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
|
WO2011088215A2
(en)
|
2010-01-13 |
2011-07-21 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
EP3064509A3
(de)
|
2010-02-23 |
2016-11-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
|
PE20130214A1
(es)
|
2010-02-23 |
2013-03-11 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011106723A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Lpath, Inc. |
Anti-paf antibodies
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
EP2566893A1
(de)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
|
US9403855B2
(en)
|
2010-05-10 |
2016-08-02 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
SG10201710439UA
(en)
|
2010-05-25 |
2018-01-30 |
Genentech Inc |
Methods of purifying polypeptides
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
ES2961381T3
(es)
|
2010-06-19 |
2024-03-11 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-GD2
|
JP2013538191A
(ja)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
病的血管新生および腫瘍細胞侵襲性の阻害のための治療法としてならびに分子イメージングおよび標的化送達のための抗DEsupR阻害剤
|
EA201370030A1
(ru)
|
2010-08-10 |
2013-06-28 |
Амген Инк. |
Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ, インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
AU2011288412A1
(en)
|
2010-08-13 |
2013-02-21 |
Medimmune Limited |
Monomeric polypeptides comprising variant Fc regions and methods of use
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
PT3556396T
(pt)
|
2010-08-31 |
2022-07-04 |
Scripps Research Inst |
Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
|
US8993727B2
(en)
|
2010-09-22 |
2015-03-31 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
RU2013126477A
(ru)
|
2010-11-08 |
2014-12-20 |
Дженентек, Инк. |
Вводимые подкожно антитела против рецептора il-6
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
EP3208282A1
(de)
|
2010-11-30 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Blut-hirn-schranke-rezeptorantikörper mit geringer affinität und verwendungen davon
|
CA2822283A1
(en)
|
2010-12-23 |
2012-06-28 |
Nestec S.A. |
Drug selection for malignant cancer therapy using antibody-based arrays
|
WO2012095432A2
(en)
|
2011-01-12 |
2012-07-19 |
Innate Pharma |
Tlr3 binding agents
|
EP2665822A1
(de)
|
2011-01-18 |
2013-11-27 |
Amgen Inc. |
Nav1.7-knockout-mäuse und ihre verwendung
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
US8916160B2
(en)
|
2011-02-14 |
2014-12-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012110843A1
(en)
|
2011-02-18 |
2012-08-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis
|
EP2684045B2
(de)
|
2011-03-09 |
2023-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur charakterisierung von patienten mit hämolyse
|
KR20140012131A
(ko)
|
2011-03-15 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
EP2691113A4
(de)
|
2011-03-31 |
2014-12-24 |
Hoffmann La Roche |
Verfahren zur verabreichung von beta7-integrin-antagonisten
|
WO2012151199A1
(en)
|
2011-05-02 |
2012-11-08 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
CN103797029B
(zh)
|
2011-05-17 |
2016-08-17 |
洛克菲勒大学 |
人类免疫缺陷病毒中和抗体及其使用方法
|
WO2012163848A1
(en)
|
2011-05-27 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of crohn's disease
|
ES2894398T3
(es)
|
2011-06-03 |
2022-02-14 |
Xoma Technology Ltd |
Anticuerpos específicos para TGF-beta
|
EP2721070A1
(de)
|
2011-06-17 |
2014-04-23 |
Harris, Adrian, L. |
Verfahren zur verbesserung des ansprechverhaltens auf strahlung in der tumortherapie mit anti-dll4-antikörpern
|
WO2012175613A1
(en)
|
2011-06-21 |
2012-12-27 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9493549B2
(en)
|
2011-07-25 |
2016-11-15 |
The Rockefeller University |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
|
US9890207B2
(en)
|
2011-07-25 |
2018-02-13 |
California Institute Of Technology |
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
|
WO2013014262A1
(en)
|
2011-07-27 |
2013-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating myhre syndrome
|
US20140271680A1
(en)
|
2011-08-12 |
2014-09-18 |
Universite Paris-Est Creteil Val De Marne |
Methods and pharmaceutical compositions for treatment of pulmonary hypertension
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
ES2553456T3
(es)
|
2011-09-02 |
2015-12-09 |
Nestec S.A. |
Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
|
PL3485903T3
(pl)
|
2011-09-23 |
2023-06-12 |
Mereo Biopharma 5, Inc. |
Środki wiążące VEGF/DLL4 i ich zastosowania
|
WO2013050441A1
(en)
|
2011-10-05 |
2013-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
|
EP2581388A1
(de)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen sPLA2-V und Gebrauch davon
|
WO2013057313A1
(en)
|
2011-10-20 |
2013-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the detection and the treatment of cardiac remodeling
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
ES2717536T3
(es)
|
2011-11-02 |
2019-06-21 |
Hoffmann La Roche |
Cromatografía de sobrecarga y elución
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
EP2782933A1
(de)
|
2011-11-22 |
2014-10-01 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur verringerung von atemwegüberreaktion
|
ES2638649T3
(es)
|
2011-11-28 |
2017-10-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
EP2602265A1
(de)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antikörper gegen Anti-sPLA2-X und Verwendungen damit
|
WO2013090293A1
(en)
|
2011-12-15 |
2013-06-20 |
The University Of Chicago |
Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
CN104066438B
(zh)
|
2011-12-22 |
2015-09-23 |
辉瑞公司 |
抗糖尿病化合物
|
WO2013092998A1
(en)
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US20130243750A1
(en)
|
2012-01-31 |
2013-09-19 |
Genentech, Inc. |
Anti-ige antibodies and methods using same
|
WO2013113898A1
(en)
|
2012-02-03 |
2013-08-08 |
Medimmune Limited |
Process for reducing antibody aggregate levels and antibodies produced thereby
|
WO2013117647A1
(en)
|
2012-02-07 |
2013-08-15 |
Innate Pharma |
Mica binding agents
|
AU2013222188A1
(en)
|
2012-02-22 |
2014-09-11 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
EP2641916A1
(de)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Neue Antikörper gegen Anti-sPLA2-IIA und Verwendungen damit
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
CA2873646C
(en)
|
2012-05-18 |
2022-04-26 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
KR102115438B1
(ko)
|
2012-05-21 |
2020-05-27 |
제넨테크, 인크. |
혈액-뇌 장벽 수송의 안전성을 개선하는 방법
|
US20150140010A1
(en)
|
2012-05-22 |
2015-05-21 |
Inserm 9Institut National De La Sante Et De La R- Echerche Medicale) |
Methods for diagnosing and treating focal segmental glomerulosclerosis
|
WO2013178736A1
(en)
|
2012-05-31 |
2013-12-05 |
Innate Pharma |
Tlr3 binding agents
|
KR20150018604A
(ko)
|
2012-06-06 |
2015-02-23 |
온코메드 파마슈티칼스, 인크. |
히포 경로를 조절하는 결합제 및 그의 용도
|
JP6498600B2
(ja)
|
2012-06-08 |
2019-04-10 |
ストロ バイオファーマ インコーポレーテッド |
部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
|
US9879068B2
(en)
|
2012-06-21 |
2018-01-30 |
California Institute Of Technology |
Antibodies targeting HIV escape mutants
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
EP2875049B1
(de)
|
2012-07-18 |
2018-12-26 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren zur vorbeugung und behandlung chronische niereninsuffizienz (ckd)
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
CA2874864C
(en)
|
2012-08-14 |
2023-02-21 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
CN109053901A
(zh)
|
2012-08-29 |
2018-12-21 |
霍夫曼-拉罗奇有限公司 |
血脑屏障穿梭体
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
MX2015003932A
(es)
|
2012-10-05 |
2015-07-23 |
Genentech Inc |
Metodos para diagnosticar y tratar la enfermedad inflamatoria intestinal.
|
JP6461804B2
(ja)
|
2012-10-18 |
2019-01-30 |
ザ ロックフェラー ユニバーシティー |
広域中和抗hiv抗体
|
US20150246118A1
(en)
|
2012-10-26 |
2015-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
|
WO2014072416A1
(en)
|
2012-11-08 |
2014-05-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bone metastases
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
JP2015537212A
(ja)
|
2012-11-15 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
イオン強度媒介のph勾配イオン交換クロマトグラフィー
|
FR2998579B1
(fr)
|
2012-11-27 |
2015-06-19 |
Commissariat Energie Atomique |
Methode pour obtenir des anticorps humains specifiques d'un antigene par immunisation in vitro
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
KR20230078823A
(ko)
|
2012-12-13 |
2023-06-02 |
이뮤노메딕스, 인코오포레이티드 |
개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
EP2951589A1
(de)
|
2013-02-01 |
2015-12-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren zur vorhersage und vorbeugung von metastasen in dreifach negativen brustkrebsen
|
ES2747920T3
(es)
|
2013-02-14 |
2020-03-12 |
Innate Pharma |
Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
|
EP2767549A1
(de)
|
2013-02-19 |
2014-08-20 |
Adienne S.A. |
Anti-CD26-Antikörper und Verwendungen davon
|
CA2899241C
(en)
|
2013-02-20 |
2023-03-28 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
RU2680267C2
(ru)
|
2013-03-15 |
2019-02-19 |
Мемориал Слоан Кеттеринг Кэнсер Сентер |
Высокоаффинные антитела к gd2
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
EP3010547B1
(de)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatische konjugation von polypeptiden
|
KR20160042871A
(ko)
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
US20160176943A1
(en)
|
2013-07-05 |
2016-06-23 |
Inserm (Insititut National De La Sante Et De La Recherche Medicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
SG10201710758PA
(en)
|
2013-07-09 |
2018-02-27 |
Annexon Inc |
Anti-complement factor c1q antibodies and uses thereof
|
EP3019522B1
(de)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antikörper mit mehreren ortsspezifischen nichtnatürlichen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
|
KR102251127B1
(ko)
|
2013-07-12 |
2021-05-11 |
제넨테크, 인크. |
이온 교환 크로마토그래피 입력 최적화의 설명
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
KR20160050062A
(ko)
|
2013-09-05 |
2016-05-10 |
제넨테크, 인크. |
크로마토그래피 재사용 방법
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
CN105744944B
(zh)
|
2013-09-09 |
2020-07-07 |
卡尼姆盖德治疗学公司 |
免疫系统调节器
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
SG11201601823TA
(en)
|
2013-09-13 |
2016-04-28 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN105848722B
(zh)
|
2013-10-02 |
2021-09-03 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
WO2015071701A1
(en)
|
2013-11-15 |
2015-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of pancreatic cancers
|
AU2015205755C1
(en)
|
2014-01-10 |
2020-08-13 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
CA2936488C
(en)
|
2014-01-14 |
2022-05-03 |
The Medical College Of Wisconsin, Inc. |
Targeting clptm1l for treatment and prevention of cancer
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3104882B1
(de)
|
2014-02-14 |
2019-06-05 |
Centrose, Llc |
Extrazelluläre gezielte wirkstoffkonjugate
|
WO2015124588A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
|
WO2015124570A1
(en)
|
2014-02-18 |
2015-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of influenza a virus infection
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
CA2939204C
(en)
|
2014-03-14 |
2023-06-27 |
Innate Pharma |
Humanized antibodies with increased stability
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
CN113604543A
(zh)
|
2014-03-27 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
用于诊断和治疗炎症性肠病的方法
|
EP3804745A1
(de)
|
2014-04-25 |
2021-04-14 |
The Brigham and Women's Hospital, Inc. |
Verfahren zur manipulation von alpha-fetoprotein (afp)
|
EP3140653B1
(de)
|
2014-05-08 |
2022-05-11 |
Novodiax, Inc. |
Direkter immunhistochemischer test
|
EP3888690A3
(de)
|
2014-05-16 |
2021-10-20 |
MedImmune, LLC |
Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
|
CA2950440A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
AU2015267047A1
(en)
|
2014-05-27 |
2017-01-05 |
Academia Sinica |
Anti-CD20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI654202B
(zh)
|
2014-05-27 |
2019-03-21 |
中央研究院 |
增進抗體功效之通用糖型之組合物及方法
|
AU2015267044A1
(en)
|
2014-05-28 |
2016-12-15 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
ES2905777T3
(es)
|
2014-05-30 |
2022-04-12 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
EP3161002A1
(de)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
Multispezifische nkp46-bindende proteine
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
KR102462743B1
(ko)
|
2014-07-09 |
2022-11-02 |
버디 바이오파마슈티칼즈, 인크. |
종양 치료용 항-pd-l1 조합
|
US10975150B2
(en)
|
2014-07-22 |
2021-04-13 |
Sutro Biopharma, Inc. |
Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
|
SG10201913611QA
(en)
|
2014-08-08 |
2020-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
EP3180359A1
(de)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Behandlung von krebs mit einem chimären gfr-alpha-4-antigenrezeptor
|
WO2016026978A1
(en)
|
2014-08-22 |
2016-02-25 |
Universite Nice Sophia Antipolis |
Methods and pharmaceutical compositions for treating drug addiction
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
CN113929782A
(zh)
|
2014-09-16 |
2022-01-14 |
依奈特制药公司 |
对淋巴细胞中抑制途径的中和
|
WO2016057398A1
(en)
|
2014-10-07 |
2016-04-14 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
CN106852149B
(zh)
|
2014-10-10 |
2021-08-27 |
依奈特制药公司 |
Cd73阻断
|
MX2017004769A
(es)
|
2014-10-15 |
2017-10-16 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.
|
WO2016062851A1
(en)
|
2014-10-23 |
2016-04-28 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
AU2015339744B2
(en)
|
2014-10-31 |
2021-03-25 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in CART cells and uses thereof
|
US11471487B2
(en)
|
2014-10-31 |
2022-10-18 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding T cells
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
EP3221361B1
(de)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Multispezifische anti-transferrin-rezeptor- / anti-bace1-antikörper und verfahren zur verwendung
|
WO2016087889A1
(en)
|
2014-12-03 |
2016-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers
|
AU2015360579A1
(en)
|
2014-12-10 |
2017-05-18 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
EP3244926A4
(de)
|
2015-01-14 |
2018-06-27 |
The Brigham and Women's Hospital, Inc. |
Behandlung von krebs mit monoklonalen-anti-lap-antikörpern
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016118191A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
WO2016128523A1
(en)
|
2015-02-12 |
2016-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
|
EP3262072A1
(de)
|
2015-02-26 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Integrin-beta7-antagonisten und methoden zur behandlung von morbus crohn
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
DK3265117T3
(da)
|
2015-03-06 |
2021-02-08 |
Canimguide Therapeutics Ab |
Immunsystemmodulatorer og præparater
|
EP3067062A1
(de)
|
2015-03-13 |
2016-09-14 |
Ipsen Pharma S.A.S. |
Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
SG10201913158PA
(en)
|
2015-04-03 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
MX2017012802A
(es)
|
2015-04-07 |
2018-04-11 |
Alector Llc |
Anticuerpos antisortilina y métodos para su uso.
|
ES2841437T3
(es)
|
2015-04-13 |
2021-07-08 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
|
JP2018519248A
(ja)
|
2015-04-22 |
2018-07-19 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Th17媒介性疾患の処置のための方法及び医薬組成物
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
CA2987403A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
PL3303619T3
(pl)
|
2015-05-29 |
2020-10-05 |
F. Hoffmann-La Roche Ag |
Metylacja promotora PD-L1 w chorobach nowotworowych
|
AU2016271101B2
(en)
|
2015-05-31 |
2021-04-01 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
EP3307779A2
(de)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33-antikörper und verfahren zur verwendung davon
|
EP3307771A2
(de)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33-antikörper und verfahren zur verwendung davon
|
CA2990511A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
CA2990518A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
EP3316885B1
(de)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
|
US10253101B2
(en)
|
2015-08-06 |
2019-04-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
EP4218777A3
(de)
|
2015-08-28 |
2023-08-23 |
The Trustees of the University of Pennsylvania |
Verfahren und zusammensetzungen für zellen, die ein chimäres intrazelluläres signalmolekül exprimieren
|
CN115960235A
(zh)
|
2015-08-28 |
2023-04-14 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
DK3353196T3
(da)
|
2015-09-22 |
2023-02-20 |
Inst Nat Sante Rech Med |
Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1
|
SG10201912150TA
(en)
|
2015-10-06 |
2020-02-27 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
EP3362082A1
(de)
|
2015-10-16 |
2018-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlicher augenkrankheiten
|
DK3365364T3
(da)
|
2015-10-23 |
2024-05-06 |
Eureka Therapeutics Inc |
Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf
|
JP7060502B2
(ja)
|
2015-10-29 |
2022-04-26 |
アレクトル エルエルシー |
抗Siglec-9抗体及びその使用方法
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
KR20180098625A
(ko)
|
2015-12-30 |
2018-09-04 |
제넨테크, 인크. |
분해가 감소된 폴리소르베이트를 갖는 제형
|
EP3405495B1
(de)
|
2016-01-21 |
2021-02-24 |
Innate Pharma |
Neutralisierung von inhibitorischen pfaden in lymphozyten
|
EP3408671B1
(de)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Verfahren zum testen t-zell-abhängiger bispezifischer antikörper
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
EP3407912B1
(de)
|
2016-01-28 |
2022-05-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur verbesserung der potenz immunologischer checkpoint-hemmer
|
JP6970099B2
(ja)
|
2016-01-28 |
2021-11-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置のための方法及び医薬組成物
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017140684A2
(en)
|
2016-02-15 |
2017-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
|
WO2017152102A2
(en)
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
KR102398425B1
(ko)
|
2016-03-08 |
2022-05-16 |
이나뜨 파르마 에스.에이. |
Siglec 중화 항체
|
WO2017157948A1
(en)
|
2016-03-14 |
2017-09-21 |
Innate Pharma |
Anti-cd39 antibodies
|
KR102408161B1
(ko)
|
2016-03-15 |
2022-06-13 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) |
대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법
|
RU2018128215A
(ru)
|
2016-03-15 |
2020-04-15 |
Иннейт Фарма |
Антитела против mica
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
EP3433615A1
(de)
|
2016-03-21 |
2019-01-30 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren zur diagnose und behandlung von sonnenpigmentflecken
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
EP3439659A1
(de)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von altersbedingten kardiometabolischen erkrankungen
|
WO2017182609A1
(en)
|
2016-04-22 |
2017-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
AU2017257254B2
(en)
|
2016-04-27 |
2022-02-24 |
Immunomedics, Inc. |
Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
EP3452512B1
(de)
|
2016-05-03 |
2023-03-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von gewebeläsionen
|
ES2912453T3
(es)
|
2016-05-06 |
2022-05-26 |
Inst Nat Sante Rech Med |
Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
EP3463452A1
(de)
|
2016-05-24 |
2019-04-10 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren und pharmazeutische zusammensetzungen zur behandlung von nicht-kleinzelligem lungenkrebs (nsclc), der mit chronisch obstruktiver lungenerkrankung (copd) koexistiert
|
EP3472197A1
(de)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antikörper mit manipulierten ch2-domänen, zusammensetzungen davon und verfahren zur verwendung davon
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
US20190271702A1
(en)
|
2016-07-28 |
2019-09-05 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of treatement of cancer disease by targetting tumor associated macrophage
|
EP3490600A1
(de)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
|
BR112019002979B1
(pt)
|
2016-08-15 |
2023-10-03 |
Genentech, Inc |
Método de cromatografia para quantificação de um tensoativo não iônico em uma composição compreendendo o tensoativo não iônico e um polipeptídeo
|
EP3500594A4
(de)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
Antikörper, bindungsfragmente und verfahren zur verwendung
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
JP2019534710A
(ja)
|
2016-09-28 |
2019-12-05 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インターロイキン2に結合する抗体およびその使用
|
WO2018065552A1
(en)
|
2016-10-06 |
2018-04-12 |
Innate Pharma |
Anti-cd39 antibodies
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
US20190233512A1
(en)
|
2016-10-12 |
2019-08-01 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
EP3529277A1
(de)
|
2016-10-21 |
2019-08-28 |
Innate Pharma |
Behandlung mit anti-kir3dl2-,wirkstoffen
|
EP3950709B1
(de)
|
2016-10-21 |
2024-02-14 |
OSE Immunotherapeutics |
Verfahren und pharmazeutische zusammensetzungen zur förderung der t-zellenantwort
|
WO2018083080A2
(en)
|
2016-11-04 |
2018-05-11 |
Innate Pharma |
Nkp46 ligand
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
EP3559032A1
(de)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimere antigenbindende proteine
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
EP3574016A2
(de)
|
2017-01-24 |
2019-12-04 |
Innate Pharma |
Nkp46-bindende mittel
|
EP3574012A1
(de)
|
2017-01-27 |
2019-12-04 |
Memorial Sloan Kettering Cancer Center |
Bispezifische her2- und cd3-bindende moleküle
|
EP3577138A1
(de)
|
2017-02-06 |
2019-12-11 |
Innate Pharma |
Immunmodulatorische antikörper-wirkstoff-konjugate, die an ein humanes mica-polypeptid binden
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3585813A1
(de)
|
2017-02-22 |
2020-01-01 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-spezifische antikörper, zusammensetzungen davon und verfahren zur herstellung und verwendung davon
|
EP3596124A1
(de)
|
2017-03-16 |
2020-01-22 |
Innate Pharma |
Zusammensetzungen und verfahren zur behandlung von krebs
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
US20200088732A1
(en)
|
2017-04-13 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Mèdicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
EP4230649A3
(de)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
|
SG11201909541WA
(en)
|
2017-04-26 |
2019-11-28 |
Eureka Therapeutics Inc |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
AU2018258049A1
(en)
|
2017-04-26 |
2019-12-12 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2018217944A1
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
EP3652207A1
(de)
|
2017-07-10 |
2020-05-20 |
Innate Pharma |
Kombinationstherapie mit antikörper gegen menschliches siglec-9 und antikörper gegen humanes nkg2a zur behandlung von krebs
|
CA3066514A1
(en)
|
2017-07-10 |
2019-01-17 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
US11827669B2
(en)
|
2017-07-19 |
2023-11-28 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
JP7122370B2
(ja)
|
2017-07-26 |
2022-08-19 |
フォーティ セブン, インコーポレイテッド |
抗sirp-アルファ抗体及び関連方法
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
TWI811229B
(zh)
|
2017-08-03 |
2023-08-11 |
美商阿列克特有限責任公司 |
抗trem2抗體及其使用方法
|
JP7299160B2
(ja)
|
2017-08-03 |
2023-06-27 |
アレクトル エルエルシー |
抗cd33抗体及びその使用方法
|
BR112020005212A2
(pt)
|
2017-09-18 |
2020-09-15 |
Sutro Biopharma, Inc. |
conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
|
KR20200090151A
(ko)
|
2017-09-20 |
2020-07-28 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
신규한 항-hla-a2 항체 및 이의 용도
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
EP3692068B1
(de)
|
2017-10-06 |
2022-12-07 |
Innate Pharma |
Herstellung der t-zellaktivität über die cd39 / cd73 - achse
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
AU2018368541A1
(en)
|
2017-11-15 |
2020-03-19 |
Innate Pharma |
Potentiating the effect of ATP release
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
PE20201339A1
(es)
|
2017-12-19 |
2020-11-25 |
Univ Rockefeller |
Variantes de dominio de fc de igg humana con funcion efectora mejorada
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
US20220153871A1
(en)
|
2018-01-04 |
2022-05-19 |
Iconic Therapeutics, Inc. |
Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
|
KR20200120641A
(ko)
|
2018-01-15 |
2020-10-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
EP3743101A2
(de)
|
2018-01-25 |
2020-12-02 |
ACM Biolabs Pte Ltd |
Ein lösliches verkapseltes antigen enthaltende polymersome sowie verfahren zu deren herstellung und verwendung
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
US20210017295A1
(en)
|
2018-03-12 |
2021-01-21 |
Memorial Sloan Kettering Cancer Center |
Bispecific binding agents and uses thereof
|
CA3092522A1
(en)
|
2018-03-13 |
2019-09-19 |
Innate Pharma |
Treatment of head and neck cancer
|
WO2019175381A1
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
US20210070819A1
(en)
|
2018-03-16 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
EP3774901A1
(de)
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma-rezeptor-antikörper, zusammensetzungen mit anti-bcma-rezeptor-antikörpern und verfahren zur herstellung und verwendung von anti-bcma-antikörpern
|
WO2019185683A1
(en)
|
2018-03-28 |
2019-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
AU2019241350A1
(en)
|
2018-03-30 |
2020-07-30 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
EP3775908A1
(de)
|
2018-04-13 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur vorhersage des ergebnisses und der behandlung von patienten mit prostatakrebs oder brustkrebs
|
IT201800004853A1
(it)
|
2018-04-24 |
2019-10-24 |
|
Metodi per trattare il cancro
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
AU2019270277A1
(en)
|
2018-05-15 |
2021-01-07 |
Innate Pharma |
Treatment of cancer
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
CA3103936A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
MX2020012107A
(es)
|
2018-06-18 |
2021-01-29 |
Innate Pharma |
Composiciones y procedimientos para el tratamiento del cancer.
|
WO2020007898A1
(en)
|
2018-07-04 |
2020-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating brain injury or neurodegenerative disease
|
SG11202012339WA
(en)
|
2018-07-13 |
2021-01-28 |
Nanjing Legend Biotech Co Ltd |
Co-receptor systems for treating infectious diseases
|
CN111372655A
(zh)
|
2018-07-13 |
2020-07-03 |
艾利妥 |
抗分拣蛋白抗体及其使用方法
|
WO2020023920A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
WO2020035345A1
(en)
|
2018-08-14 |
2020-02-20 |
Innate Pharma |
Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
|
US20220105176A1
(en)
|
2018-09-12 |
2022-04-07 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
AR116526A1
(es)
|
2018-09-27 |
2021-05-19 |
Tizona Therapeutics |
Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y métodos de uso de anticuerpos anti-hla-g
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
WO2020079164A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
BR112021009373A2
(pt)
|
2018-11-16 |
2021-08-17 |
Memorial Sloan Kettering Cancer Center |
anticorpos para mucina-16 e métodos de uso dos mesmos
|
EP3887399A1
(de)
|
2018-11-30 |
2021-10-06 |
Institut Gustave-Roussy |
Kombinationstherapie aus anti-neuropilin-1 und anti-programmierter zelltod-1 zur behandlung von krebs
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
WO2020132560A2
(en)
|
2018-12-21 |
2020-06-25 |
Aim Immunotech Inc. |
Compositions and methods for cancer therapy
|
WO2020136145A2
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Leucocyte immunoglobulin-like receptor neutralizing antibodies
|
EP3918323A4
(de)
|
2019-01-30 |
2022-12-28 |
TrueBinding, Inc. |
Anti-gal3-antikörper und verwendungen davon
|
EP3927748A1
(de)
|
2019-02-21 |
2021-12-29 |
Trishula Therapeutics, Inc. |
Kombinationstherapie mit anti-cd39-antikörpern und anti-pd-1- oder anti-pd-l1-antikörpern
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
US20220154153A1
(en)
|
2019-03-22 |
2022-05-19 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
JP2022527345A
(ja)
|
2019-04-03 |
2022-06-01 |
オレガ・バイオテック |
Pd1阻害剤及びil-17b阻害剤に基づく複合療法
|
CN113711037A
(zh)
|
2019-04-18 |
2021-11-26 |
基因泰克公司 |
抗体效力测定
|
KR20220002959A
(ko)
|
2019-04-23 |
2022-01-07 |
이나뜨 파르마 에스.에이. |
Cd73 차단 항체
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
PE20220336A1
(es)
|
2019-05-03 |
2022-03-14 |
Celgene Corp |
Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y metodos de fabricacion y uso del mismo
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
WO2020229546A1
(en)
|
2019-05-14 |
2020-11-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
EP3821250B1
(de)
|
2019-05-16 |
2022-05-04 |
ProciseDx Inc. |
Testverfahren zum nachweis von vcam-1 und alpha-2-makroglobulin in blut
|
JP2022532381A
(ja)
|
2019-05-16 |
2022-07-14 |
プロサイセデクス インコーポレイティド |
Vcam-1及びカルプロテクチンのための分析検出方法
|
EP3973290A1
(de)
|
2019-05-23 |
2022-03-30 |
ProciseDx Inc. |
Testverfahren zum nachweis von humanem serumalbumin, vitamin d, c-reaktivem protein und anti-transglutaminase-antikörper
|
TW202112799A
(zh)
|
2019-06-05 |
2021-04-01 |
美商建南德克公司 |
過載層析管柱之再生方法
|
EP3980779A1
(de)
|
2019-06-06 |
2022-04-13 |
ProciseDx Inc. |
Nachweis von hämoglobin a1c (hba1c) in blut
|
JP2022536490A
(ja)
|
2019-06-10 |
2022-08-17 |
ストロ バイオファーマ インコーポレーテッド |
5H-ピロロ[3,2-d]ピリミジン-2,4-ジアミノ化合物およびその抗体コンジュゲート
|
EP3983410A1
(de)
|
2019-06-17 |
2022-04-20 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-aminderivate und verwandte verbindungen als toll-like- rezeptor (tlr) 7/8-agonisten sowie antikörper-wirkstoff-konjugate davon zur verwendung in der krebstherapie und -diagnose
|
EP3990922A1
(de)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Nachweis von anti-tnf-alpha biologika und anti-wirkstoff-antikörpern
|
CN114040754A
(zh)
|
2019-06-28 |
2022-02-11 |
基因泰克公司 |
用于稳定液体蛋白质制剂的组合物及方法
|
EP4004051A4
(de)
|
2019-07-19 |
2023-08-23 |
Oncoresponse, Inc. |
Immunmodulatorische antikörper und verfahren zur verwendung davon
|
EP4034151A1
(de)
|
2019-09-27 |
2022-08-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verwendung von müllerschen hemmstoff-inhibitoren zur behandlung von krebs
|
EP3804754A1
(de)
|
2019-10-09 |
2021-04-14 |
OSE Immunotherapeutics |
Cmklr1-agonisten mit resolvin-e1-ähnlicher fähigkeit und ihre therapeutischen anwendungen
|
JP2022552422A
(ja)
|
2019-10-16 |
2022-12-15 |
コーセプト セラピューティクス, インコーポレイテッド |
選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球/リンパ球比を正常化する方法
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
US20230070181A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of cancer disease by targeting an epigenetic factor
|
EP4110810A1
(de)
|
2020-02-28 |
2023-01-04 |
Orega Biotech |
Kombinationstherapien auf basis von ctla4- und il-17b-inhibitoren
|
WO2021175924A1
(en)
|
2020-03-03 |
2021-09-10 |
Active Biotech Ab |
Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
|
WO2021194861A1
(en)
|
2020-03-23 |
2021-09-30 |
Genentech, Inc. |
Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
|
CN115916820A
(zh)
|
2020-03-23 |
2023-04-04 |
基因泰克公司 |
用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
|
JP2023518812A
(ja)
|
2020-03-23 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
WO2021233962A1
(en)
|
2020-05-19 |
2021-11-25 |
Institut Curie |
Methods for the diagnosis and treatment of cytokine release syndrome
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP4171527A1
(de)
|
2020-06-25 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung und diagnose pathologischer zustände in zusammenhang mit intensivem stress
|
TW202216771A
(zh)
|
2020-06-26 |
2022-05-01 |
德商拜耳廠股份有限公司 |
用於治療應用之ccr8抗體
|
JP2023537115A
(ja)
|
2020-08-13 |
2023-08-30 |
イナート・ファルマ・ソシエテ・アノニム |
抗cd73抗体を使用する癌処置方法
|
US20230312689A1
(en)
|
2020-08-26 |
2023-10-05 |
National University Corporation Kumamoto University |
Human antibody or antigen-binding fragment thereof against coronavirus spike protein
|
US20230340149A1
(en)
|
2020-09-07 |
2023-10-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of treatment of inflammatory bowel diseases
|
JP2023541921A
(ja)
|
2020-09-17 |
2023-10-04 |
ジェネンテック, インコーポレイテッド |
Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果
|
EP4232064A1
(de)
|
2020-10-21 |
2023-08-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
C-terminale sparc-fragmente zur behandlung von krebs
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
EP4240761A1
(de)
|
2020-11-05 |
2023-09-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Verwendung von il-6-inhibitoren zur behandlung des akuten brustsyndroms bei patienten mit sichelzellanämie
|
KR20230113564A
(ko)
|
2020-11-06 |
2023-07-31 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
다낭성 난소 증후군(pcos)의 진단 및 치료 방법
|
WO2022112469A1
(en)
|
2020-11-27 |
2022-06-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring of toxic epidermal necrolysis
|
TW202244060A
(zh)
|
2021-01-20 |
2022-11-16 |
美商昂科里斯龐司公司 |
免疫調節抗體及其用途
|
EP4284513A1
(de)
|
2021-01-26 |
2023-12-06 |
Universite Brest Bretagne Occidentale |
Neuartige stim1-spleissvarianten und verwendungen davon
|
EP4314049A1
(de)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7-konstrukte und verwendungen davon
|
AU2022246048A1
(en)
|
2021-03-26 |
2023-08-31 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
WO2022218957A1
(en)
|
2021-04-12 |
2022-10-20 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
WO2022218998A1
(en)
|
2021-04-13 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating hepatitis b and d virus infection
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
EP4340876A1
(de)
|
2021-05-19 |
2024-03-27 |
Sutro Biopharma, Inc. |
Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
KR20240019297A
(ko)
|
2021-06-09 |
2024-02-14 |
이나뜨 파르마 에스.에이. |
Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
CN117980333A
(zh)
|
2021-06-11 |
2024-05-03 |
基因泰克公司 |
用st2拮抗剂治疗慢性阻塞性肺疾病的方法
|
CN118103397A
(zh)
|
2021-07-08 |
2024-05-28 |
舒泰神(加州)生物科技有限公司 |
特异性识别tnfr2的抗体及其用途
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
AU2022378932A1
(en)
|
2021-10-27 |
2024-05-02 |
Assistance Publique Hopitaux De Marseille |
Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
|
WO2023089032A1
(en)
|
2021-11-19 |
2023-05-25 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
WO2023102077A1
(en)
|
2021-12-01 |
2023-06-08 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
WO2023104904A2
(en)
|
2021-12-08 |
2023-06-15 |
Genclis |
The sars-cov-2 and variants use two independent cell receptors to replicate
|
WO2023192622A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2023247651A1
(en)
|
2022-06-21 |
2023-12-28 |
TME Pharma AG |
Methods for treating a tumor in a subject
|
EP4306640A1
(de)
|
2022-06-21 |
2024-01-17 |
TME Pharma AG |
Verfahren zur behandlung eines tumors in einem patienten
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024074498A1
(en)
|
2022-10-04 |
2024-04-11 |
Imcheck Therapeutics |
Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer
|